Get to know our clinical trials
Study to test whether zongertinib helps people with advanced cancers characterized by alterations in HER2
THE AIM OF THIS STUDY IS TO FIND OUT HOW EFFECTIVE AND SAFE ZONGERTINIB IS IN VARIOUS TYPES OF CANCERS. PATIENTS WITH THE SAME TYPE OF CANCER WILL BE IN THE SAME GROUP.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE 2, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZONGERTINIB (BI 1810631) FOR THE TREATMENT OF SELECTED SOLID TUMORS WITH HER2 MUTATIONS, OVEREXPRESSION OR AMPLIFICATION.
- Code EudraCT: 2023-510429-14-00
- Protocol number: 1479-0009
- Promoter: Boehringer Ingelheim España, S.A.
- Molecule/Drug: zongertinib (BI 1810631)
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.